BIGNOTTI, Eliana
 Distribuzione geografica
Continente #
NA - Nord America 4.162
EU - Europa 1.775
AS - Asia 1.773
SA - Sud America 255
AF - Africa 38
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 8.013
Nazione #
US - Stati Uniti d'America 4.066
CN - Cina 606
SG - Singapore 550
PL - Polonia 385
IT - Italia 306
DE - Germania 238
BR - Brasile 218
UA - Ucraina 215
HK - Hong Kong 187
FI - Finlandia 148
VN - Vietnam 129
GB - Regno Unito 107
FR - Francia 86
BD - Bangladesh 65
CA - Canada 61
TR - Turchia 55
IN - India 52
RU - Federazione Russa 47
EE - Estonia 46
IE - Irlanda 45
ES - Italia 27
SE - Svezia 25
ID - Indonesia 23
NL - Olanda 21
IQ - Iraq 20
MX - Messico 19
ZA - Sudafrica 17
AR - Argentina 15
BE - Belgio 14
CZ - Repubblica Ceca 14
AT - Austria 11
JP - Giappone 11
LT - Lituania 11
BG - Bulgaria 7
EC - Ecuador 7
PK - Pakistan 7
KG - Kirghizistan 6
SA - Arabia Saudita 6
TW - Taiwan 6
JO - Giordania 5
KR - Corea 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
CR - Costa Rica 4
LK - Sri Lanka 4
MY - Malesia 4
OM - Oman 4
TN - Tunisia 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
CL - Cile 3
EU - Europa 3
IL - Israele 3
JM - Giamaica 3
LV - Lettonia 3
MA - Marocco 3
NG - Nigeria 3
PT - Portogallo 3
PY - Paraguay 3
RO - Romania 3
UY - Uruguay 3
VE - Venezuela 3
AL - Albania 2
BB - Barbados 2
BH - Bahrain 2
CO - Colombia 2
ET - Etiopia 2
HN - Honduras 2
HU - Ungheria 2
KE - Kenya 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MU - Mauritius 2
NP - Nepal 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AQ - Antartide 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DZ - Algeria 1
EG - Egitto 1
GT - Guatemala 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LY - Libia 1
MT - Malta 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
RS - Serbia 1
SV - El Salvador 1
TH - Thailandia 1
TJ - Tagikistan 1
TO - Tonga 1
Totale 8.013
Città #
Fairfield 408
Ashburn 405
Warsaw 383
Singapore 316
Woodbridge 297
San Jose 221
Houston 213
Seattle 201
Chandler 194
Hong Kong 169
New York 167
Jacksonville 147
Cambridge 136
Wilmington 132
Ann Arbor 121
Beijing 119
The Dalles 110
Dearborn 109
Helsinki 108
Los Angeles 94
Princeton 74
Munich 61
Brescia 57
Nanjing 47
Tallinn 46
Dublin 45
Lauterbourg 42
Istanbul 40
Shanghai 38
Dallas 37
Milan 36
Des Moines 35
Buffalo 31
Council Bluffs 31
Chicago 30
Hangzhou 30
Ho Chi Minh City 30
San Francisco 29
Toronto 28
São Paulo 27
London 26
Santa Clara 26
Dong Ket 24
Jinan 24
Hanoi 23
Moscow 22
Nanchang 21
Shenyang 21
Orem 20
Kunming 19
Rome 18
Turku 18
Denver 15
Montreal 15
San Diego 15
Tianjin 15
Hebei 14
Brussels 13
Central 13
Chennai 13
Redondo Beach 13
Changsha 12
Jakarta 12
Brooklyn 11
Johannesburg 11
Guangzhou 10
Monmouth Junction 10
Phoenix 10
Poplar 10
Tokyo 10
Belo Horizonte 9
Mexico City 9
Paris 9
Stockholm 9
Zhengzhou 9
Badalona 8
Boston 8
Charlotte 8
Jiaxing 8
Mumbai 8
Nuremberg 8
Vienna 8
Ankara 7
Atlanta 7
Brno 7
Hefei 7
Leawood 7
Manchester 7
Ningbo 7
Rio de Janeiro 7
Amsterdam 6
Bishkek 6
Frankfurt am Main 6
Haiphong 6
Kilburn 6
Kyiv 6
New Delhi 6
Olomouc 6
Verona 6
Baghdad 5
Totale 5.544
Nome #
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues 361
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Zhao S1, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD 356
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 331
A prognostic regulatory pathway in stage I epithelial ovarian cancer: New hints for the poor prognosis assessment 233
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 219
Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer 213
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts 211
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone 210
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 204
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma 203
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. 201
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes 196
Gene expression profiling to improve prognostic characterization of olfactory neuroblastoma and to define new targetable pathways 193
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 188
Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues. 186
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 183
Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. 182
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma 181
RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients 180
Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial 178
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 177
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 174
Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma 174
Overexpression of mammaglobin B in epithelial ovarian carcinomas. 172
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 168
Mammaglobin B expression in human endometrial cancer 167
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy 161
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome 153
Claudin-7 expression in human epithelial ovarian cancer 147
Claudin 7 downregulation is predictive of distant metastasis in high-grade serous carcinoma patients 146
Improved Risk Prediction in Human Papillomavirus-Associated Endocervical Adenocarcinoma Through Assessment of Binary Silva Pattern-based Classification: An International Multicenter Retrospective Observational Study Led by the International Society of Gynecological Pathologists (ISGyP) 142
Gene expression profiling of olfactory neuroblastoma helps identify prognostic pathways and define potentially therapeutic targets 142
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer 141
LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study 137
Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients 133
Uso di miRNA come biomarcatori per la diagnosi e prognosi del carcinoma orale a cellule squamose 127
Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients 120
Integrated mutational landscape analysis of uterine leiomyosarcomas 115
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients 112
L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma 109
Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes 97
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors 95
The Oxford Classic can identify HGSOC patients who may benefit from EMT-targeting therapies 88
Correction for Li et al., Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors 87
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy 85
Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy 82
Circulating Serum Micro-RNA as Non-Invasive Diagnostic Biomarkers of Endometriosis 72
Identification of optimal reference RNAs to normalize miRNA expression data by qRT-PCR in formalin-fixed, paraffin-embedded lymph node tissue 71
Oxford Classic-Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions 57
Development of a diagnostic model based on serum microRNAs for the diagnosis of endometriosis 50
Serum miRNA-based diagnostic models for endometriosis: from discovery to validation 13
Totale 8.123
Categoria #
all - tutte 34.179
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.179


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202150 0 0 0 0 0 0 0 0 0 0 0 50
2021/2022442 64 91 7 3 5 27 28 21 15 59 38 84
2022/2023493 76 32 25 32 47 102 8 52 69 6 24 20
2023/2024619 36 19 64 54 33 165 34 37 80 37 9 51
2024/20251.157 22 20 19 201 79 124 74 45 119 74 215 165
2025/20262.552 239 212 162 354 318 210 410 88 151 230 120 58
Totale 8.123